Advertisement

Related Videos

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Amit Sanyal, MD: A Clinician’s Perspective

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Peter Clark, MA, MD, FRCP: A Payer Perspective

Advertisement

Advertisement




Oct
18
Today In Oncology
Verifying the Seen and Unseen by AI in Cancer Imaging
AI-Extracted Chart Data for Expanding Surgical Oncology Learnings
Even Highly Curable Childhood Leukemias Take a Substantial Toll on Families
Two Studies Show Breast Cancer Survival and Mortality Gaps Are Widening Between Rural and Urban Areas
Lung Cancer Specialist Apar Kishor Ganti, MD, Shares His Insights
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo